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ABSTRACT
Several alternative techniques exist to reconstruct skull defects. The complication rate of the cra-
nioplasty procedure is high and the search for optimal materials and techniques continues. To
report long-term results of patients who have received a cranioplasty using autologous adipose-
derived stem cells (ASCs) seeded on beta-tricalcium phosphate (betaTCP) granules. Between 10/
2008 and 3/2010, ﬁve cranioplasties were performed (four females, one male; average age 62.0
years) using ASCs, betaTCP granules and titanium or resorbable meshes. The average defect size
was 8.1 3 6.7 cm2. Patients were followed both clinically and radiologically. The initial results were
promising, with no serious complications. Nevertheless, in the long-term follow-up, three of the
ﬁve patients were re-operated due to graft related problems. Two patients showed marked resorp-
tion of the graft, which led to revision surgery. One patient developed a late infection (7.3 years
post-operative) that required revision surgery and removal of the graft. One patient had a success-
fully ossiﬁed graft, but was re-operated due to recurrence of the meningioma 2.2 years post-
operatively. One patient had an uneventful clinical follow-up, and the cosmetic result is satisfactory,
even though skull x-rays show hypodensity in the borders of the graft. Albeit no serious adverse
events occurred, the 6-year follow-up results of the ﬁve cases are unsatisfactory. The clinical results
are not superior to results achieved by conventional cranial repair methods. The use of stem cells in
combination with betaTCP granules and supporting meshes in cranial defect reconstruction need to
be studied further before continuing with clinical trials. STEM CELLS TRANSLATIONAL MEDICINE
2017;6:1576–1582
SIGNIFICANCE STATEMENT
In this article we report long-term results of five patients who received a cranioplasty using
autologous adipose-derived stem cells seeded on beta-tricalcium phosphate granules. The initial
results were promising, with no serious complications. Nevertheless, the 6-year follow-up
results of the five cases are unsatisfactory. The use of this strategy for cranial defect reconstruc-
tion must be studied further before continuing with clinical trials and before applying the
method in clinical practice.
INTRODUCTION
Skull restoration remains a challenge for neurosur-
geons and plastic surgeons [1]. The number of
patients in need of cranioplasty is increasing
because of continuous improvements in neurosur-
gical critical care and a growing number of decom-
pressive craniectomies performed [1]. Common
complications in cranial repair surgery include for
example infection, wound dehiscence, intracranial
hemorrhage, resorption, and/or dislocation of the
graft [2–5]. The reported complication rate of cra-
nioplasties today is 16%–40%, with a general reop-
eration rate of 25% [6–10]. Patients’ autologous
removed and stored bone has been considered as
the gold standard in cranial vault reconstruction,
but there are studies reporting superior results
achieved with synthetic materials such as hydroxy-
apatite, bioactive ﬁber-reinforced composite, poly-
methylmethacrylate, or titanium [9, 11, 12].
Our aim was to overcome common problems
associated with conventional cranioplasties by
creating bone from patients’ own adipose-derived
stem cells (ASCs), beta-tricalcium phosphate
(betaTCP) granules and supporting meshes [13,
14]. In recent years, ASCs have been under exten-
sive study in regenerative medicine [15–18]. They
are easily retrieved in high numbers from fat
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tissue and expanded in vitro, which makes them an attractive tool
in tissue reconstruction [14, 19, 20]. However, scientiﬁc evidence
in terms of safety and efﬁcacy of ASC use in regenerative medi-
cine is still limited [14, 20–24].
We performed ﬁve cranioplastic surgeries using ASCs seeded
in betaTCP granules supported by resorbable or titanium meshes
to patients who had moderate-sized cranial defects of varying eti-
ologies. The grafts seemed to be successful in short-term follow-
up, both clinically and radiologically, but already the mid-term
results showed increased graft resorption [13, 14]. In the current
study, our objective is to report the long-term results (6.1–7.4
years) of this method.
MATERIALS AND METHODS
Five patients, four females and one male, average age 62.0 years
(range, 54–75 years), underwent cranioplasty using this novel
technique between 10/2008 and 3/2010. The average defect size
was 8.1 3 6.7 cm2 (range, 6.5 3 3.7 – 9.0 3 9.3; Table 1). Pri-
mary diagnoses and indications for cranioplasties are presented
in Table 1.
Adipose tissue harvests from subcutaneous abdominal fat
(approx. 100 ml) were performed approximately 3 weeks prior to
the cranioplasty procedure. The fat together with 60 ml of autolo-
gous serum was transported to Regea Institute for regenerative
medicine, University of Tampere for stem-cell isolation and expan-
sion. None of the cranioplasty constructs was supplemented with
rhBMP-2.
ASC Isolation and Preparation for Transplantation
ASCs were isolated and expanded in vitro in clean rooms accord-
ing to standard operating procedures and following Good Manu-
facturing Practice guidelines at Regea. Details of the isolation and
expansion procedures with minor modiﬁcations are described in a
previous publication [20]. Recombinant collagenase NB 6 (Invitro-
gen, Paisley, Scotland, United Kingdom; Good Manufacturing Prac-
tice grade; SERVA Electrophoresis GmbH, Heidelberg, Germany)
was utilized to mince and digest the adipose tissue. The isolated
ASCs were expanded for approximately 22 days in basal media
containing Dulbecco’s modiﬁed Eagle medium/F-12 (Gibco Invitro-
gen, Paisley, Scotland, United Kingdom) with 15% of autologous
Table 1. Characteristics of patients and procedures
Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex F M F F F
Age at primary
cranioplasty
60 59 62 75 54
Diagnosis Skull hemangioma Frontal meningioma Acute SDH Cranial base
meningioma
Skull meningioma
Indication for
cranioplasty
Primary operation Loosening of the acryl
graft
Bone ﬂap
infection
Bone ﬂap infection Primary operation
Defect size (length3
height, cm)
6.93 6.4 9.03 7.5 8.93 6.8 6.53 3.7 9.03 9.3
Inner mesh No No Resorbable Resorbable Titanium
Outer mesh Titanium Resorbable Resorbable Resorbable Resorbable
Total number ASCs
implanted (ASCs
per ml)
4,140,000
(37,637)
8,712,000
(108,900)
3,982,500
(49,781)
7,821,000
(391,050)
2,812,500
(28,125)
Indication for re-
operation
Late infection Partial resorption
and loosening
of the graft
— Total resorption Recurrence of the
meningioma in
the dura
Time between cranio-
plasty and re-operation
(years)
7.3 0.9 — 2.0 2.2
Re-operation
technique
Revision, removal
of the graft
Titanium mesh applied
on the defect
— Titanium cranioplasty Re-craniotomy and
excision of the dural
meningioma
Histological analysis
of the graft
Osteonecrosis and
acute to subacute
osteomyelitis
Partly necrotic islets
containing loose
collagen and poorly
maintained osteoblasts.
Focally some well-
formed bone trabeculae
containing vital
osteocytes
— — —
Notice Frontal sinus opened in
the primary operation
and ﬁlled with bone
cement
Remaining graft was
hard and ﬁxated
with screws into a tita-
nium mesh.
Resorption of
the graft in
the skull
x-ray
Abdominal hematoma
at the adipose tissue
harvest site
Graft was successfully
ossiﬁed and had grown
into the surrounding
bone
Clinical follow-up
(years)
7.4 6.8 6.2 6.5 6.1
Abbreviations: —, no data; ASC, adipose-derived stem cell.
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serum, without antibiotics. Subsequently the cells were passaged
on conﬂuence and detached mechanically with a cell scraper and
prepared for cell transplantation. To allow cell attachment, approx-
imately 15 3 106 cells of passages 3 to 4 were combined with
60 ml of betaTCP granules (Chronos1, porosity 60%, granule size
1.4–2.8 mm; Synthes, Oberdorf, Switzerland) 48 hours before the
operation. The cells were tested negative for Mycoplasma contam-
ination as determined by a Mycoplasma PCR kit (VenorGem;
Minerva Biolabs GmbH, Berlin, Germany) and cell sterility and
endotoxins were tested by Biovian Ltd. (Turku, Finland) according
to methods described in the European Pharmacopoeia (Council of
Europe, Strasbourg, France) [25].
In Vitro Analyses and Live/Dead Staining
For the in vitro analyses, ASCs from all patients were expanded in
basal media, except in the osteogenic differentiation capacity
assessment, in which commercially available human serum (Bio-
Whittaker; Lonza, Walkersville, Maryland), was used because of
the limited amount of autologous serum.
Cell attachment to the betaTCP granules and the cell viability
were studied using Live/Dead staining before the operation.
Brieﬂy, the cell-biomaterial combination was incubated with a
mixture of CellTracker green (5-chloromethylﬂuorescein diacetate)
and ethidium homodimer (Molecular Probes, Eugene, Oregon).
The viable cells (green ﬂuorescence) and dead cells (red ﬂuores-
cence) were detected with a ﬂuorescence microscope.
Flow Cytometric Surface Marker Expression Analysis
ASCs were further expanded in vitro and were analyzed at passages
4 to 5 by ﬂow cytometry (FACSAria; BD Biosciences, Erembodegem,
Belgium). Monoclonal antibodies against CD9-PE, CD10-PECy7,
CD13-PE, CD14-PECy, CD19-PECy7, CD29-APC, CD49d-PE, CD73-PE,
CD90-APC, CD106-PE-Cy5, CD146-PE, and CD166-PE (BD Bioscien-
ces); CD45-FITC (Miltenyi Biotech, Bergisch Gladbach, Germany);
CD31-FITC, CD34-APC, CD44-FITC, HLA-ABC-PE, and HLA-DR-PE
(Immunotools GmbH, Friesoythe, Germany); and CD105-PE (R&D
Systems Inc., Minneapolis, Minnesota) were used. Analysis was
performed on 10,000 cells per sample. The positive expression was
deﬁned as the level of ﬂuorescence greater than 99% of the corre-
sponding unstained cell sample.
Osteogenic Differentiation Capacity Assessment
For the in vitro osteogenic differentiation analyses, surplus cells
were maintained in osteogenic media containing basal media
supplemented with 15% human serum, 50 mM L-ascorbic acid
2-phosphate (Sigma-Aldrich, St. Louis, Missouri), 10 mM beta-
glycerophosphate (Sigma-Aldrich), and 100 nM dexamethasone
(Sigma-Aldrich). Control cell cultures were maintained in basal
media supplemented with human serum. The cells were seeded
at a density of 2.5 3 103 cells/cm2 and cultures were subse-
quently analyzed by alkaline phosphatase staining at day 14.
Cranioplasty Procedure
All patients received routine preoperative cefuroxime antibiotic
1.5 g intravenously (Zinacef, GlaxoSmithKline, United Kingdom). At
ﬁrst the dura was exposed in all cases. In Patient 1, a hemangioma
was removed with the outer and inner diploe of bone, and the
opened frontal sinus was cranialized and ﬁlled with bone cement
(NORIAN Reinforced Fast Set Putty, Synthes, Oberdorf, Switzer-
land, http://www.synthes.com). In Patient 2, a loosened acryl
graft was removed. In Patients 3 and 4, the skin was carefully dis-
sected loose from the dura. In Patient 5, a bone meningioma was
resected. Next, ASCs combined with betaTCP granules were
applied in the defect (Fig. 1). The numbers of implanted ASCs are
presented in Table 1. To keep the betaTCP granules in place,
resorbable custom-molded mesh (PLGA, 85:15 poly (L-lactide-co-
glycolide)) (RapidSorb, Synthes, Oberdorf, Switzerland, http://
www.synthes.com) or titanium mesh was used either in single or
bilaminate fashion (Table 1). Meshes were secured with either
titanium or resorbable screws.
Follow-Up
Patients were followed at 1 week, 1, 6, and 12 months after
surgery and annually thereafter. During the ﬁrst year,
Figure 1. Intraoperative photograph of a meningioma resection site ﬁlled with autologous adipose stem cell-seeded beta-tricalcium phos-
phate (b-TCP) granules (Patient 5).
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Houndsﬁeld units (HU) were measured from CT studies to
assess bone density. After the ﬁrst year, imaging studies were
done based on clinical consideration, and HU measurement
was not systematically continued. Histological samples of the
graft were obtained from two re-operated patients (Patients 1
and 2). The formalin-ﬁxed, parafﬁn-embedded sample sections
were stained with hematoxylin and eosin and periodic acid-
Schiff, and histologically evaluated.
Ethical Considerations
The study was approved by the board of the local hospital district,
and Finnish Medicines Agency (FIMEA) was informed about the
procedures. Before surgery, the patients were informed about the
procedures, which they approved and to which they gave their
written consent.
RESULTS
In Vitro Results
The viability and adherence of the ASCs transplanted with the
betaTCP granules to the patients was conﬁrmed by Live/Dead
staining. The ﬂow cytometry showed that the cells were
homogenous in morphology by side-scatter and forward-scatter
parameters. However the immunophenotype showed variability
between patients. Nevertheless, strong positive expression
(>90%) was seen in surface markers CD10, CD13, Cd29, CD44,
CD49d, CD73,CD90, CD105, CD106, and CD166. Moderate positive
expression (>10%, <90%) was seen for markers CD 9, CD106 and
CD146. No expression, or low expression (<10%) was seen for
markers CD31, CD34, CD45, and major histocompatibility complex
class I isotype human leukocyte antigen DR, suggesting low detec-
tion of cells of hematopoietic and angiogenic lineages. Moreover,
CD14 and CD 19 (hematopoietic markers) showed great variability
in surface marker expression, ranging from low to moderate.
According to alkaline phosphatase staining, all patients’ cell
samples possessed the capacity to differentiate toward the osteo-
genic lineages.
Clinical Results
During the follow-up period (average 6.6 years, range 6.1–7.4), all
patients except one were re-operated. We observed signs of
resorption of the graft in three cases out of ﬁve (Table 1). One
graft (Patient 1) which was surgically explored due to late infection
was relatively soft and was supported to a large degree by the
titanium mesh. Microbiological cultures of the infected graft were
negative and the infection was successfully treated by surgical
removal of the graft combined with cefuroxime and levoﬂoxacin
(Tavanic, Sanoﬁ, United Kingdom) antibiotics. Two patients had
clinical loosening of the graft (Patients 2 and 4). The graft in one
patient showed radiological resorption at the borders but the clin-
ical result was good (Patient 3; Fig. 2A, 2B). One patient was re-
operated due to recurrence of the meningioma in the dura mater
underlying the graft (Patient 5), but the graft as such was success-
ful (Table 1).
Histological Results
A histological sample of the graft was obtained from two re-
operated patients. The ﬁndings of the graft from Patient 1 were
consistent with osteonecrosis and acute to subacute
Figure 2. (A): Reformatted CT image of the head 13 months post-
operatively (Patient 3). Partial resorption of the graft is seen at the
basal area. (B): Skull x-ray 6 years post-operatively (Patient 3) shows
substantial resorption of the graft at the borders.
Figure 3. Low-power histological appearance of the biopsy speci-
men from the skull lesion of patient 1 shows hypocellular degener-
ated collagenous material and loose ﬁbrinous tissue. Some of the
spherical necrotic tissue islands are partially mineralized. Fungus
hyphae are present in the ﬁbrous tissue (arrow). There is an inﬂam-
matory polymorphonuclear leukocyte inﬁltrate at the top of the
photomicrograph. Hematoxylin and eosin (H&E) staining. Original
magniﬁcation340. Scale bar5 100 lm.
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osteomyelitis. Nonviable degenerated tissue with polymorphonu-
clear inﬂammatory inﬁltrates and organizing granulation tissue as
well as radiating septate hyphae characteristic of Aspergillus infec-
tion were seen (Fig. 3). The graft from Patient 2 showed mainly
degenerated osteoid-like tissue islets containing loose collagen
and poorly maintained osteoblasts. However, focally there were
some well-formed bone trabeculae containing vital osteocytes
(Fig. 4). There were no features suggestive of neoplastic change.
DISCUSSION
Bone tissue engineering techniques with or without ASCs have
been studied actively during past decades [26–28]. ASCs are multi-
potent cells that are recognized as potentially beneﬁcial in wide
variety of medical therapies in reconstructive surgery [27–30]. The
potential of these cells has evoked great enthusiasm and high
expectations in both scientiﬁc and commercial circles. However, in
general clinical applications of stem cells in reconstructive surgery
have been limited to small case series with varying results and/or
short follow-up periods [14, 31–33]. Among the published studies,
there is a great variability in, for example, stem cell sources, defect
sites and sizes, indications, cell carriers, and use of growth factors
that makes it difﬁcult to draw a solid conclusion on stem cell effec-
tiveness in bone tissue engineering [26]. Additionally, there has
been concern about the safety and efﬁcacy of stem cells in clinical
applications [21, 24, 33, 34].
This long-term follow-up report on ﬁve patients receiving cra-
nioplasty using ASCs, betaTCP granules and supporting meshes
suggests that the method as such is safe. The short-term results
(less than a year) were promising and the bone density of the
grafts (measured by HUs) tended to increase [13]. However, in
long follow-up, the outcome of the cranioplasties was unsatisfac-
tory in most cases partially due to poor ossiﬁcation and partially
due to infection or tumor recurrence.
Two of the ﬁve patients showed marked clinical and radiologi-
cal resorption of the graft that led to re-operation (Patients 2 and
4). Nevertheless, histology of the re-ﬁxated graft in Patient 2
showed focally well-formed bone trabeculae containing vital
osteocytes. One patient had radiological graft resorption, but the
graft was ﬁrm on palpation, and no re-operation was needed in 7
years follow-up (Patient 3; Fig. 2A, 2B). One patient had a late
infection of the graft (>7 years post-operatively) that is not likely
to be related to the cranioplasty method (Patient 1). The late
infection was most likely due to unsuccessful cranialization of the
frontal sinus. Her frontal sinus was opened in the primary opera-
tion and ﬁlled with artiﬁcial material, which may have been the
cause of the infection. One patient (Patient 5), who had recur-
rence of the meningioma 2.2 years after the primary operation,
was found to have a clinically ossiﬁed graft that had attached well
to defect margins and prevented unfastening of the graft in the
re-operation. This patient had a titanium inner mesh, which prob-
ably played a role in the success of her case.
There are several questions that must be solved before clinical
trials regarding the effectiveness of this strategy are continued.
First, how could ossiﬁcation be induced and enhanced, and how
can the bone forming capacity of the ASCs be stimulated in this
setup? ASCs themselves may stimulate bone formation not only
by differentiating into bone cells but also by secreting paracrine
factors that enhance ossiﬁcation and vascularization. We decided
to use ASCs mainly because of their great accessibility and low
patient morbidity when compared with other mesenchymal cell
sources such as bone marrow or periosteum. The in vitro, in vivo
and clinical bone-forming capacity of ASCs in combination with
various scaffold materials have been reported by many authors
[14, 20, 35–41]. In this series, the ﬂow cytometric characterization
of the ASCs expanded in autologous serum corresponded to previ-
ously published results for ASCs [42, 43]. According to ﬂow cytom-
etry, and alkaline phosphatase staining results, the cells were of
mesenchymal origin and had a capacity to differentiate into the
osteoblastic lineage. There was individual variability in the num-
bers of implanted cells ranging from 28,125 cells/ml to 391,050
cells/ml (average 123,098 cells/ml). In the future, it is vital to ﬁnd
the optimal doses of ASCs and biomaterial granules to achieve
effective ossiﬁcation. Also, the role of growth factors such as
rhBMP-2 in reconstructive surgery is indeterminate and safety
concerns have emerged in clinical applications [44]. In this series
growth factors were not used. The effectiveness of the construct
might be further increased by soaking it in venous blood prior to
implantation [45, 46]. Moreover, an intact periosteum would be
beneﬁcial for bone formation but its role in this setup remains
unclear [47].
The purpose of the scaffold in reconstructive tissue engineer-
ing is to provide mechanical support for cell proliferation, migra-
tion, and activity by mimicking extra cellular matrix [48, 49].
Ideally, the scaffold provides a template for bone formation, and
calcium phosphate based materials are considered ideal in this
regard. So far, dozens of calcium phosphate materials including
betaTCP have been investigated both in vitro and in vivo [50–52].
We used granular betaTCP partly because of its bioresorbability
and large surface area compared to solid scaffolds. Granules also
molded well to the defects. Moreover, there is prior evidence of
the use of betaTCP in craniomaxillofacial surgery [20, 53, 54]. The
failure of the graft ossiﬁcation of Patients 2 and 4 may be due to
too rapid resorption of betaTCP granules which in turn may be
related to the use of resorbable and less rigid supporting meshes
in their cases. In future studies, it is pivotal to ﬁnd an optimal scaf-
fold material to support ossiﬁcation in cranial area [55, 56].
The supporting mesh (mono/bilaminate) plays probably a piv-
otal role in the success of the graft in this setup. The main
Figure 4. The biopsy specimen from patient 2 shows mainly spheri-
cal islands of degenerated collagenous osteoid-like tissue where
smudgy appearing nuclei are visible. However, two well-formed tra-
beculae of woven bone containing viable osteocytes are seen
(arrows). Hematoxylin and eosin (H&E) staining. Original magniﬁcation
3100. Scale bar5 100 lm.
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advantage of a resorbable mesh, such as RapidSorb is that there
will be no artiﬁcial material left in the graft site in the long run.
However, resorbable mesh may lose its strength rather rapidly; for
example RapidSorb has 85% strength left after 8 weeks, 40% at 15
weeks, and <10% after 20 weeks [57], which may result in
increased micromotion, which potentially prohibits sound bone
bridging due to continuous disruption of the fragile initial bone
struts and early vessel formation. On the other hand, rapidly
resorbing PLGA constructs may accumulate acidity due to hydroly-
sis of the mesh which in turn may cause hydrolysis of the newly
formed mineral deposits and strong activation of osteoclasts.
Based on our current experience, we believe that the use of a rigid
mesh such as titanium is necessary for damping dural pulsations to
offer optimal circumstances for bone formation when granular
scaffold material is used. On the other hand, titanium and other
materials may provide surfaces supporting the migration of osteo-
blasts [58, 59]. In our series, the titanium-containing constructs
(Patients 1 and 5) had good intermediate follow-up results and the
observed osteolysis was due to non-reconstruction related causes
(Patient 1) and recurrent meningioma (Patient 5). In patient 2, a
single layer of resorbable mesh may have provided insufﬁcient sta-
bility to avoid micromotion sufﬁciently, hence failure of appropri-
ate integration of graft in time which led to resorption and
loosening of the graft. Both Patients 3 and 4 had a double layer of
resorbable mesh. The discrepancy of the results between Patient 3
(resorption only at the borders) and Patient 4 (complete resorption
of the graft) may be due to markedly higher age of the Patient 4,
and lower functionality of her ASCs. However, the limited number
of patients and high number of confounding factors makes it
impossible to draw solid conclusions in regard to optimal mesh
material or technique.
The critical size of the defect for this method remains indeter-
minate. Large size probably hinders blood supply to central parts
of the graft, which may be crucial for bone formation. The defect
size in our series was relatively large (average 8.1 3 6.7 cm2);
however, it was considerably smaller than the average defect size
following decompressive hemicraniectomy, which is a common
neurosurgical procedure leading to calvarial defects [60, 61]. Obvi-
ously, there are several additional issues to consider before the
method is taken into clinical use.
CONCLUSION
Conventional cranioplasties have high complication rates, which
encourage searching for novel techniques.We performed ﬁve cra-
nioplasties using ASCs, betaTCP granules and titanium or resorb-
able mesh. The 6-year results of most of these cases are
unsatisfactory. There were no clear indications that this procedure
stimulated ossiﬁcation or that ACSs or their progeny produced
new bone. Nevertheless, there were no serious adverse events,
and all patients recovered well from the surgeries. The use of this
strategy for cranial defect reconstruction must be studied further
before continuing with clinical trials and before applying the
method in clinical practice.
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